Docetaxel versus androgen receptor pathway inhibitors as first-line therapy for metastatic castration-resistant prostate cancer after doublet therapy: a multicenter retrospective study from Saudi Arabia
Shouki Bazarbashi, Ahmed S. Abdelmotal, Tarek Arabi, Waleed Fallatah, Noura Alzannan, Tusneem Elhassan, Mohamed Aseafan, Mohammed Mahroos, Maram Aljishi, Albatool Busbaih, Rajaa Aldandan, Muhammad Shahzad Rauf, Fahad A Almugbel, Faisal Azam, Mubarak Almansour · 2025
Read Docetaxel versus androgen receptor pathway inhibitors as first-line therapy for metastatic castration-resistant prostate cancer after doublet therapy: a multicenter retrospective study from Saudi Arabia by Shouki Bazarbashi, Ahmed S. Abdelmotal, Tarek Arabi, Waleed Fallatah, Noura Alzannan, Tusneem Elhassan, Mohamed Aseafan, Mohammed Mahroos, Maram Aljishi, Albatool Busbaih, Rajaa Aldandan, Muhammad Shahzad Rauf, Fahad A Almugbel, Faisal Azam, Mubarak Almansour (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12751458.txt.
Description
Shouki Bazarbashi and fourteen co-authors compare two first moves when prostate cancer turns resistant after modern doublet therapy, in this 2025 Saudi multicenter study. Patients whose cancer progressed despite hormone therapy plus a receptor-blocking drug in the sensitive phase form a growing group with no settled next step: another receptor drug, or chemotherapy with docetaxel.
The retrospective study covered sixty men at three cancer centers. Twenty-eight took the drug route, thirty-two the chemotherapy. Response rates were nearly identical, around thirty-eight percent. Chemotherapy trended better on progression-free and overall survival without reaching significance. One subgroup stood out: men with visceral spread lived significantly longer on docetaxel, a median 14.4 versus 5.9 months. Statistical modeling flagged prior hormone response depth among survival predictors. The authors call for randomized trials and biomarker-guided sequencing.
Catalog record
| CREATOR | Shouki Bazarbashi, Ahmed S. Abdelmotal, Tarek Arabi, Waleed Fallatah, Noura Alzannan, Tusneem Elhassan, Mohamed Aseafan, Mohammed Mahroos, Maram Aljishi, Albatool Busbaih, Rajaa Aldandan, Muhammad Shahzad Rauf, Fahad A Almugbel, Faisal Azam, Mubarak Almansour |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 22 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |